WBRT and systemic treatments (chemotherapy and/or EGFR TKIs) are the treatment options for polymetastatic involvement of the brain. Treatment approaches are not influenced by the timing of onset ...

EGFR has been the most extensively ... X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.

is led by AstraZeneca’s fast-growing EGFR tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib). Amivantamab (formerly JNJ-6372) is a bispecific or double-headed antibody, combining an EGFR ...

The trial will continue to assess OS as a key secondary endpoint. While EGFR-TKIs have significantly improved outcomes in the 1st-line setting, mechanisms of resistance and disease progression are ...

EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...